Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on March 27, 2025. The filing was submitted on March 28, 2025. The Company is a foreign private issuer reporting under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a share repurchase executed as part of an existing buyback programme. The transaction was effected through Citigroup Global Markets Limited under a non-discretionary agreement entered into on February 24, 2025.
- Shares Purchased (March 27, 2025): 847,000 ordinary shares.
- Price Range: Lowest price paid was 1,464.50p; highest price paid was 1,479.50p.
- Volume-Weighted Average Price (VWAP): 1,472.39p.
- Trading Venue: London Stock Exchange (XLON).
- Treasury Shares Held: Following this purchase, the Company holds 185,636,390 ordinary shares in treasury.
- Shares in Issue: 4,129,578,456 (excluding Treasury shares).
- Total Voting Rights: 4,129,578,456.
Since the commencement of the current agreement on February 24, 2025, the Company has purchased a total of 16,566,087 ordinary shares.
Material Changes
The filing does not report material changes to the Company's financial position, revenue, or operations. The primary change reported is the reduction in the number of shares in issue and the increase in treasury shares resulting from the repurchase programme.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding future performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. Investors are directed to the "Risk factors" section on pages 277 to 285 of the GSK 2024 Annual Report on Form 20-F for a detailed description of these risks.
Important Facts for Investors to Verify
- Confirm the total remaining authorization under the current buyback programme and the total amount spent to date.
- Verify the impact of the increased treasury share count on earnings per share (EPS) calculations in future reports.
- Review the "Risk factors" in the 2024 Annual Report on Form 20-F as referenced in the cautionary statement.
- Note that the total number of voting rights (4,129,578,456) serves as the denominator for shareholder notification thresholds under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.